More about

Duke University

News
November 22, 2022
3 min read
Save

Low household income may predict higher risk for 30-day HF readmission

Low household income may predict higher risk for 30-day HF readmission

CHICAGO — Adults with an index HF hospitalization were 20% more likely to be readmitted within 30 days for a HF-specific cause if they lived in a low-income area as opposed to a high-income one, researchers reported.

News
November 17, 2022
2 min read
Save

Botulinum toxin injection does not prevent postoperative AF: NOVA

Botulinum toxin injection does not prevent postoperative AF: NOVA

CHICAGO — Epicardial botulinum toxin type A injected into epicardial fat pads after cardiac surgery did not suppress incidence of postoperative atrial fibrillation compared with placebo, according to findings from the NOVA study.

News
November 11, 2022
2 min read
Save

In-hospital peer-to-peer consult may improve guideline-directed therapy in HFrEF

In-hospital peer-to-peer consult may improve guideline-directed therapy in HFrEF

CHICAGO — A clinician level peer-to-peer consultation may increase use of and optimize guideline-directed medical therapy in patients with HFrEF hospitalized for any cause compared with usual care, a speaker reported.

News
November 09, 2022
3 min read
Save

Black women less likely to receive guideline-concordant therapy for ovarian cancer

Black women less likely to receive guideline-concordant therapy for ovarian cancer

Black women in the U.S. appeared less likely than white women to receive guideline-concordant treatment for ovarian cancer, according to a study published in Journal of the National Comprehensive Cancer Network.

News
November 07, 2022
3 min read
Save

Revaccination guidance after cell therapy established for some, ‘evolving’ for others

Revaccination guidance after cell therapy established for some, ‘evolving’ for others

Guidelines on revaccination after cell therapy are clear for some patients but lack evidence-based consensus for others, according to an expert in infectious disease who spoke at NCCN 2022 Annual Congress: Hematologic Malignancies.

News
November 06, 2022
5 min read
Save

Precision testing strategy strongly benefits stable patients with suspected CAD

Precision testing strategy strongly benefits stable patients with suspected CAD

CHICAGO — In stable symptomatic patients with suspected CAD, a precision testing strategy was linked to a 70% reduction in death, MI or catheterization without obstructive CAD at 1 year compared with the usual testing, researchers reported.

News
November 06, 2022
2 min read
Save

Methylprednisolone does not reduce odds of poor outcomes in infant heart surgery

Methylprednisolone does not reduce odds of poor outcomes in infant heart surgery

CHICAGO — In infants undergoing heart surgery with cardiopulmonary bypass, the use of the steroid methylprednisolone did not reduce odds of a worse outcome compared with placebo, according to the STRESS trial.

News
November 05, 2022
3 min read
Save

Loop diuretic choice does not reduce all-cause death in HF: TRANSFORM-HF

Loop diuretic choice does not reduce all-cause death in HF: TRANSFORM-HF

CHICAGO — A treatment strategy of torsemide vs. furosemide did not improve long-term clinical outcomes for adults hospitalized with HF, including all-cause mortality and all-cause hospitalization, researchers reported.

News
November 04, 2022
5 min read
Save

Overcoming physician ‘discomfort’: What rheumatologists need to know about birth control

Overcoming physician ‘discomfort’: What rheumatologists need to know about birth control

Following the Supreme Court’s decision in June overturning Roe v. Wade, communication regarding effective and safe birth control in certain patients, including those with lupus and other rheumatic disease, has become immensely important.

News
November 03, 2022
7 min read
Save

Q&A: Trial to assess phage therapy in patients with cystic fibrosis

Q&A: Trial to assess phage therapy in patients with cystic fibrosis

A trial to assess bacteriophage, or “phage,” therapy, which utilizes a virus to target specific bacteria and leave behind other bacteria and human cells, is underway among patients with cystic fibrosis, according to an NIH press release.

View more